Navigation Links
Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
Date:7/18/2012

197944 have also been completed, which suggest an excellent margin of safety and tolerability.

Clive Dix, Chief Executive Officer of Convergence Pharmaceuticals, added: "We are delighted to announce the successful completion of Phase I clinical studies with CNV2197944.  We now plan to shortly initiate Phase II clinical trials with CNV2197944.  This will be the second compound originating from the spin-out from GSK in October 2010 that has successfully progressed to proof of concept in the chronic pain area, which is in real need for efficacious and safe pain treatments."  

The need for new drug treatments for chronic pain

The Pain therapeutic area encompasses any disease where pain is a major symptom. The unmet medical need for patients in pain is enormous, with the greatest need being for a more effective therapy that is well tolerated and safe over a long period of time. Within the pain marketplace, current pain treatments are unsatisfactory; overall efficacy is poor (typically 1-2 point reductions on a 10 point scale) and satisfactory to less than 50% of patients. Whilst treatments, such as opioids and non-steroidal anti-inflammatory drugs, are available on the market, many patients obtain little or no relief from these existing analgesics and often such drugs are associated with adverse events, side effects and addiction concerns. This highlights the importance of Convergence Pharmaceuticals' goals to be a world leader in the development of novel, efficacious analgesics with improved pharmacology and safety profiles.

About chronic pain

Currently, more than 1.5 billion people worldwide suffer from chronic pain of varying degrees. Among all types of chronic pain, neuropathic pain stands out with approximately 3-4.5% of the global population affected, with incidence rate increasing in line with increased age of the population. With the unmet clinical need so high, the demand for better pain management therapies, add
'/>"/>

SOURCE Convergence Pharmaceuticals Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Convergence of Art, Science and Beer
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
4. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
6. Access Pharmaceuticals to Report New MuGard Clinical Trial Data This Week at the MASCC/ISOO Symposium in New York City
7. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
8. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
9. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
10. Questcor Pharmaceuticals Expands Repurchase Program
11. Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 Regulus Therapeutics ... company leading the discovery and development of innovative medicines ... results and highlights for the quarter ended June 30, ... financial markets close. Regulus will host ... 2014, at 5:00 pm Eastern Daylight Time to discuss ...
(Date:7/30/2014)... N.Y. and PARIS , ... and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced ... and Drug Administration (FDA) rare pediatric disease priority review ... submission for alirocumab.  The priority review voucher entitles the ... provides for an expedited 6-month review from the filing ...
(Date:7/30/2014)... 2014 W. R. Grace & ... the REVELERIS® Prep purification system , a ... and other researchers to perform both flash and ... , With the REVELERIS® Prep purification system, researchers ... modes with a simple touch of the screen, ...
(Date:7/30/2014)... , July 30, 2014  Decision Resources ... and medical directors in the United ... of biosimilar market penetration will be the level ... (MCOs) and the expected lower cost to patients. ... biosimilars that meet their pricing expectations in order ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Grace Launches New REVELERIS® Prep Purification System 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... March 17 The following was issued,today by the ... president & CEO, Greater Baltimore Committee, 140 company ... WHAT:, The third annual Greater Baltimore Region Bioscience ... 8:00 a.m. / Breakfast & Registration, 8:45 - ...
... 17 Mercury Therapeutics,Inc. (MTI), a company ... targeted drugs, announces that it has retained ... on its strategic and partnering,opportunities, with the ... This appointment follows a significant amount ...
... ST. LOUIS, March 17 (Nasdaq: SIAL ) ... holding its 2008 Annual,Business Review on Wednesday, March 19, ... at 2909 Laclede, St. Louis, Mo. 63103, The ... by 12:30 p.m. CDT,and will also be webcast over ...
Cached Biology Technology:Greater Baltimore Committee to Announce Winners of Third Baltimore Region Bioscience Awards at Ceremonies on March 18 2Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities 2Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities 3
(Date:7/30/2014)... Queen in Lewis Carroll,s Through the Looking Glass, ... University of Singapore improved a 35-year-old ecology model ... to millions of years. , The new model, ... the "Red Queen Effect," an evolutionary hypothesis introduced ... suggests that organisms must constantly increase their fitness ...
(Date:7/30/2014)... A deep-sea octopus protected and tended her eggs until ... published July 30, 2014 in the open-access journal ... Aquarium Research Institute and colleagues. , Octopuses typically have ... females protect and take care of their fertilized eggs ... eggs for 1 to 3 months, but little is ...
(Date:7/30/2014)... Chemical Society (ACS) announced today that David L. Kaplan, ... Biomaterials Science & Engineering as editor-in-chief. With the ... new journal will feature high-quality research in the rapidly ... naturally derived materials that interact with living or biological ... reflects the tremendous growth in the field of biomaterials ...
Breaking Biology News(10 mins):Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3Deep-sea octopus has longest-known egg-brooding period 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... is also available in Chinese on EurekAlert! ... A new laser-beam steering system that aims and focuses bursts ... has been demonstrated by collaborating researchers from Duke University and ... Applied Physics Letters , published by the American Institute of ...
... the RMS Titanic, which is contributing to its deterioration. ... the exterior of ships and underwater metal structures such ... findings in the latest issue of the International ... 8 December, isolated the micro-organisms from a ,rusticle, collected ...
... book, Illinois Birds: A Century of Change, literally took 100 ... Illinois was conducted from 1906-1909. It was repeated from 1956-1958 ... When the 100-year anniversary of that first survey was approaching, ... seized the window of opportunity to do it again and ...
Cached Biology News:Tiny laser light show illuminates quantum computing 2New microscopic life aboard the RMS Titanic 2New book on 100 years of Illinois birds 2New book on 100 years of Illinois birds 3New book on 100 years of Illinois birds 4
...
... Rabbit Antibody to CRF ... with the ovine CRF sequence ... Cells and fibres are found ... of rat brain in colchicine ...
...
Alexa Fluor 647 anti-mouse Qa-2...
Biology Products: